Last reviewed · How we verify
NCT03950687
Study of rESP Injection for the Treatment of Anemia in Chronic Renal Failure Patients With Hemodialysis
Phase 2 trial testing Recombinant Human Erythropoiesis Injection (CHO cell) in Chronic Renal Failure With Hemodialysis in 150 participants. Status unknown.
30 June 2020
Quick facts
| Lead sponsor | Shenyang Sunshine Pharmaceutical Co., LTD. |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 150 |
| Start date | 24 June 2019 |
| Primary completion | 30 June 2020 |
| Estimated completion | 30 December 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- Recombinant Human Erythropoiesis Injection (CHO cell) — full drug profile →
- Recombinant Erythropoiesis Stimulating Protein Injection(CHO cell) — full drug profile →
Conditions studied
- Chronic Renal Failure With Hemodialysis — all drugs for Chronic Renal Failure With Hemodialysis →
Sponsor
Shenyang Sunshine Pharmaceutical Co., LTD. — full company profile →
Who can join
Adults 18 to 75, any sex, with Chronic Renal Failure With Hemodialysis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A phase 2, randomized, open label, active comparator parallel controlled study to explore the dosage regiment of rESP, and evaluate its efficacy, safety and pharmacokinetic characteristics in the treatment of anemia in chronic renal failure patients with hemodialysis
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03950687
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Recombinant Human Erythropoiesis Injection (CHO cell)
Trials testing the same drug.
- NCT04231292 — A Phase 2 Clinical Study of Pegerythropoietin Injection (RD01) for the Treatment of Anemia in Chronic Renal Failure Pati · Phase 2 · unknown
Other Shenyang Sunshine Pharmaceutical Co., LTD. trials
Trials by the same sponsor.
- NCT07487545 — Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of SSS67 in Healthy Adult Participants Via S · Phase 1 · not yet recruiting
- NCT07445308 — The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NM · Phase 1, PHASE2 · not yet recruiting
- NCT07171606 — A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients · Phase 2 · recruiting
- NCT07038005 — A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors · Phase 1 · recruiting
- NCT07022002 — SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03950687 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shenyang Sunshine Pharmaceutical Co., LTD.
- Last refreshed: 9 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03950687.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing